CXCL13 and urothelial carcinoma: Previous studies have discovered that combinatorial biomarkers (ARID1A mutation plus CXCL13 expression) may improve prediction capability for urothelial carcinoma patients receiving immune checkpoint inhibitors (27), and IL6 may be the most promising predictive biomarker of peptide vaccines for colorectal cancer (28).